Last reviewed · How we verify
Carboplatin or Cisplatin
Carboplatin and cisplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and triggering cancer cell death.
Carboplatin and cisplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and triggering cancer cell death. Used for Ovarian cancer, Non-small cell lung cancer, Head and neck cancer.
At a glance
| Generic name | Carboplatin or Cisplatin |
|---|---|
| Also known as | chemotherapeutic drug, chemotherapy |
| Sponsor | Second Hospital of Shanxi Medical University |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are platinum compounds that enter cancer cells and covalently bind to DNA, creating intrastrand and interstrand cross-links. This DNA damage activates apoptotic pathways and prevents cell division. Carboplatin has a similar mechanism to cisplatin but with a different pharmacokinetic profile and generally lower nephrotoxicity and ototoxicity.
Approved indications
- Ovarian cancer
- Non-small cell lung cancer
- Head and neck cancer
- Testicular cancer
- Breast cancer
- Bladder cancer
Common side effects
- Myelosuppression (thrombocytopenia, neutropenia, anemia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Alopecia
- Electrolyte abnormalities (hypomagnesemia, hypokalemia)
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin or Cisplatin CI brief — competitive landscape report
- Carboplatin or Cisplatin updates RSS · CI watch RSS
- Second Hospital of Shanxi Medical University portfolio CI